Events

Date: Wednesday, October 4, 2023 Time: 1:00pm - 2:00pm ET TITLE: An injectable, extended half-life recombinant, glycopegylated factor VIII concentrate for Hemophilia A OBJECTIVE: Provide a clinical overview of Esperoct that supports prophylactic, on-demand and perioperative management indications in adults and children. TARGET AUDIENCE: All HTC Staff SPEAKER: Parin Chikani, PharmD, MBA Medical Account Director, Read the full article...

Date: Thursday, October 12, 2023 Time: 1:00pm - 2:00pm ET TITLE: A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B OBJECTIVE: Provide a clinical review of Rebinyn that supports prophylaxis, on-demand and perioperative indication in adults and children TARGET AUDIENCE: All HTC Staff Read the full article...

Date: Tuesday, October 24, 2023 Time: 2:00pm - 3:00pm ET TITLE: A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy OBJECTIVES: Highlighting both Efanesoctocog Alfa’s pediatric study, the XTEND-Kids data that were presented at ISTH 2023, as well as an observational study of patients who switched from current Read the full article...